|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,264.90 INR | -0.26% |
|
+2.75% | +11.29% |
| 07-06 | Glenmark Pharmaceuticals Launches Olanzapine for Injection | MT |
| 06-17 | Glenmark Pharmaceuticals Launches Methylene Blue Injection in US | MT |
| Market Cap | 641B 6.72B 5.88B 5.42B 5.03B 9.55B 9.68B 64.87B 25.25B 315B 25.23B 24.68B 1,091B | P/E 2026 |
44.2x | P/E 2027 * | 27.4x |
|---|---|---|---|---|---|
| Enterprise Value | 602B 6.31B 5.52B 5.09B 4.72B 8.97B 9.09B 60.9B 23.7B 295B 23.68B 23.16B 1,024B | EV / Sales 2026 |
3.51x | EV / Sales 2027 * | 3.62x |
| Free-Float |
51.03% | Yield 2026 |
0.12% | Yield 2027 * | 0.24% |
Last Transcript: Glenmark Pharmaceuticals Limited
| 1 day | -0.26% | ||
| 1 week | +2.75% | ||
| Current month | +2.75% | ||
| 1 month | +4.06% | ||
| 3 months | +7.13% | ||
| 6 months | +7.18% | ||
| Current year | +11.29% |
| 1 week | 2,142.8 |  | 2,293.9 |
| 1 month | 2,101 | | 2,293.9 |
| Current year | 1,842 | | 2,474 |
| 1 year | 1,792.6 | | 2,474 |
| 3 years | 661 | | 2,474 |
| 5 years | 348.5 | | 2,474 |
| 10 years | 161.65 | | 2,474 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 31/12/1999 | |
Anurag Mantri
DFI | Director of Finance/CFO | 54 | 26/05/2025 |
Indrajit Bose
PSD | President | - | 14/09/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Cherylann Pinto
BRD | Director/Board Member | 58 | - |
| Chairman | 56 | 11/05/2011 | |
| Director/Board Member | 85 | 13/08/2009 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.26% | +2.75% | +21.76% | +228.60% | 6.72B | |
| -0.49% | +2.20% | +13.30% | +83.78% | 48.11B | |
| -1.41% | +6.57% | +71.07% | +120.76% | 37.88B | |
| -1.39% | -0.93% | -3.89% | +42.24% | 12.47B | |
| +0.44% | +3.63% | +15.44% | +98.02% | 12B | |
| +1.25% | +2.76% | +34.19% | +120.25% | 9.03B | |
| +0.65% | +2.74% | +23.31% | +49.16% | 7.24B | |
| +0.41% | +2.95% | +56.10% | -2.71% | 7.09B | |
| -0.62% | +21.06% | -16.02% | +24.43% | 6.54B | |
| -1.75% | -3.16% | +24.73% | +133.20% | 4.42B | |
| Average | -0.32% | +4.88% | +24.00% | +89.77% | 15.15B | |
| Weighted average by Cap. | -0.55% | +4.35% | +29.67% | +92.51% |
| 2026 | 2027 * | |
|---|---|---|
| Net sales | 153B 1.61B 1.41B 1.29B 1.2B 2.28B 2.31B 15.5B 6.03B 75.16B 6.03B 5.9B 261B | 167B 1.75B 1.53B 1.41B 1.31B 2.49B 2.52B 16.89B 6.57B 81.91B 6.57B 6.43B 284B |
| Net income | 20.53B 215M 189M 174M 161M 306M 310M 2.08B 809M 10.08B 808M 791M 34.94B | 23.22B 243M 213M 196M 182M 346M 351M 2.35B 915M 11.4B 914M 894M 39.52B |
| Net Debt | -39.29B -412M -361M -332M -308M -586M -594M -3.98B -1.55B -19.29B -1.55B -1.51B -66.87B | -37.1B -389M -341M -314M -291M -553M -560M -3.76B -1.46B -18.21B -1.46B -1.43B -63.14B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 07/07/26 | ₹2,264.90 | -0.26% | 770,737 |
| 06/07/26 | ₹2,270.90 | +2.71% | 600,450 |
| 03/07/26 | ₹2,211.00 | +0.68% | 632,010 |
| 02/07/26 | ₹2,196.00 | +1.58% | 526,651 |
| 01/07/26 | ₹2,161.90 | -1.92% | 455,357 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GLENMARK Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
